EISAI BAN2401-G000-301
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
